Pera A, Seevers R H, Meyer K, Hall C, Bekerman C, Anderson T M, Katzen H, Laakso L, Pinsky S M
Radiology. 1985 Sep;156(3):783-6. doi: 10.1148/radiology.156.3.3839588.
We developed and evaluated a new procedure for imaging gastric ulcer disease with technetium 99m-labeled sucralfate. The new method employs direct in vivo labeling of sucralfate instead of in vitro labeling using human serum albumin, as previously reported in the literature. Tests using hydrochloric acid and a rabbit ulcer model showed the efficacy of the direct in vivo labeling technique and the ability of the tagged material to bind to ulcers, respectively. In 26 studies using humans with sucralfate labeled directly in vivo, 15 gave true-negative results and 11 gave true-positive results. Of 14 studies using humans with in vitro labeled sucralfate, three gave true-negative results, three gave true-positive results, and the results of eight were either false-negative or could not be interpreted because of high levels of activity remaining in the stomach. We suggest that the direct in vivo labeling method significantly improves the sucralfate gastric ulcer imaging technique.
我们研发并评估了一种用99m锝标记的硫糖铝对胃溃疡疾病进行成像的新方法。该新方法采用硫糖铝的直接体内标记,而非如文献中先前报道的那样使用人血清白蛋白进行体外标记。使用盐酸和兔溃疡模型的测试分别显示了直接体内标记技术的有效性以及标记物质与溃疡结合的能力。在26项对人体内硫糖铝进行直接体内标记的研究中,15项给出了真阴性结果,11项给出了真阳性结果。在14项对人体内硫糖铝进行体外标记的研究中,3项给出了真阴性结果,3项给出了真阳性结果,8项的结果为假阴性或因胃内残留的高活性而无法解读。我们认为直接体内标记法显著改进了硫糖铝胃溃疡成像技术。